Why the study?
Does ticagrelor-based DAPT reduce fatal or irreversible ischemic and bleeding events compared to clopidogrel-based DAPT in ACS patients with diabetes mellitus following PCI, stratified by CYP2C19 genotype?
Does ticagrelor-based DAPT reduce fatal or irreversible ischemic and bleeding events compared to clopidogrel-based DAPT in ACS patients with diabetes mellitus following PCI, stratified by CYP2C19 genotype?
CYP2C19 genotype testing can identify ACS patients with diabetes who derive a net clinical benefit from ticagrelor over clopidogrel following PCI.
Answers are grounded in this paper and cite their sources.
May support CYP2C19-guided ticagrelor preference in diabetic ACS; leaves open need for randomized confirmation.
PURPOSE: This study evaluates the impact of CYP2C19 genotype on the outcomes of ticagrelor versus clopidogrel-based dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients with diabetes mellitus (DM). METHODS: A total of 10,376 ACS patients with DM treated with ticagrelor (N = 2931) or clopidogrel (N = 7445) following percutaneous coronary intervention (PCI) were included. Patients were categorized by CYP2C19 genotype into non-carriers (N = 4326) and loss-of-function (LOF) allele carriers (N = 6050). The primary outcome was a composite of fatal or irreversible ischemic and bleeding events at 12 months, including cardiac death, myocardial infarction, stroke, and Bleeding Academic Research Consortium (BARC) types 3 or 5 bleeding. RESULTS: Among patients with normal CYP2C19 enzyme function, ticagrelor use compared with clopidogrel was not associated with a reduction of fatal or irreversible ischemic and bleeding events (hazard ratio [HR], 1.04; 95 % confidence interval [CI], 0.70 to 1.55; p = 0.85) with excessive risk of BARC type 2 bleeding (HR, 1.72; 95 % CI, 1.13 to 2.63; p = 0.01). Among patients carried CYP2C19 loss-of-function (LOF) alleles, those treated with ticagrelor were associated with a lower risk of fatal or irreversible ischemic and bleeding events (HR, 0.69; 95 % CI, 0.50 to 0.95; p = 0.02) and all-cause death (HR, 0.58; 95 % CI, 0.34 to 0.97; p = 0.04), albeit with a higher incidence of BARC type 2 bleeding (HR, 1.86; 95 % CI, 1.38 to 2.51; p = 0.0001). CONCLUSIONS: The CYP2C19 genotype could be used to identify potential patients who would derive benefit from the ticagrelor-based antiplatelet strategy. Further research is warranted to trade off in bleeding complications from potent P2Y12 inhibitors.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: